Codexis doses first subjects in Phase 1a Trial of CDX-6114

Codexis - Nestlé Health Science’s partner in enzyme discovery – announced today that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being developed for the management of phenylketonuria (PKU).

Please view the full release on the Codexis website:
http://ir.codexis.com/news-releases/news-release-details/codexis-doses-first-subjects-phase-1a-trial-cdx-6114